Lytix Biopharma AS (OSL:LYTIX)
8.90
-0.08 (-0.89%)
Aug 1, 2025, 4:25 PM CET
Accolade Revenue
Lytix Biopharma AS had revenue of 608.00K NOK in the twelve months ending March 31, 2025, down -95.81% year-over-year. In the year 2024, Lytix Biopharma AS had annual revenue of 11.13M with 178.98% growth.
Revenue (ttm)
608.00K
Revenue Growth
-95.81%
P/S Ratio
999.23
Revenue / Employee
76.00K
Employees
8
Market Cap
607.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.13M | 7.14M | 178.98% |
Dec 31, 2023 | 3.99M | -7.04M | -63.82% |
Dec 31, 2022 | 11.03M | -8.28M | -42.87% |
Dec 31, 2021 | 19.31M | 15.23M | 373.91% |
Dec 31, 2020 | 4.07M | -2.27M | -35.73% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Medistim ASA | 603.92M |
Nordhealth AS | 545.88M |
Photocure ASA | 532.69M |
Vistin Pharma ASA | 440.66M |
Omda AS | 442.14M |
ArcticZymes Technologies ASA | 102.97M |
Gentian Diagnostics ASA | 163.38M |
Nykode Therapeutics AS | 87.09M |